HIV and AIDS Research News & Events
Learn about upcoming meetings relevant to HIV malignancies and recent news about NCI HIV/AIDS and HIV malignancy research.
25th International KSHV Conference
June 19-23, 2023
Dar es Salaam, Tanzania
Abstract Submission Deadline
April 10, 2023
14th AORTIC International Conference on Cancer in Africa
November 2-6, 2023
Dr. Robert Yarchoan delivers an opening plenary at the 2023 AACR meeting. He provided an overview of the history of Kaposi sarcoma (KS) and Kaposi's sarcoma-associated herpesvirus (KSHV) diseases in people living with HIV. The plenary also discussed the advances in treating these diseases.
Malignancies in People with HIV: Successes and Challenges at the Intersection of Virology, Immunology, and Oncology
Anal cancer diagnosis in the United States increased in men aged 50 and older.
State Variation in Squamous Cell Carcinoma of the Anus Incidence
and Mortality, and Association With HIV/AIDS and Smoking in the
Infection-unrelated cancers overtook infection-related cancers in people living with HIV in South Africa after 54 years of age.
Age and cancer incidence in 5.2 million people living with HIV: the South African cancer
AIDS-NHL patients with the diffuse large B cell lymphoma (DLBCL) tumor subtype had decreased plasma levels of extracellular vesicles bearing PD-L1, compared to those with Burkitt's lymphoma.
Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL
Lenalidomide is active in HIV-Kaposi sarcoma with manageable adverse events.
AMC-70: Lenalidomide is Safe and Effective in HIV-Associated Kaposi Sarcoma
Latest on the Anal Cancer/HSIL Outcomes Research (ANCHOR) Study:
Results from the ANCHOR study found that treating precancerous lesions reduces anal cancer development Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
NCI's ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV
A low CD/CD8 ratio up to 24 months before cancer diagnosis was independently associated with increased cancer risk in people living with HIV.
CD/CD8 Ratio and Cancer Risk Among Adults with HIV
NCI congratulates Dr. Enrique Mesri, Director of the University of Miami/Argentina AIDS Malignancies Consortium, for his lifetime achievement award (RAICES) from the Government of Argentina for his contributions to the country’s science in HIV/AIDS malignancies.
Frederick National Laboratory scientists were part of a multi-institutional collaboration that has identified a second patient
whose natural immune response to HIV infection appears to have cured the patient of the disease.
Second HIV patient appears to have cured herself with natural immunity